SANXING(601567)
Search documents
三星医疗(601567) - 2020 Q4 - 年度财报
2021-04-19 16:00
Financial Performance - The net profit for 2020 was CNY 720,993,369.94, with a statutory reserve of CNY 72,099,336.99, resulting in a distributable profit of CNY 838,862,881.03 after dividend payments[6]. - The company reported an increase in retained earnings from CNY 481,148,349.21 at the beginning of the year[6]. - The company's operating revenue for 2020 was approximately ¥7.09 billion, an increase of 4.22% compared to ¥6.81 billion in 2019[24]. - The net profit attributable to shareholders for 2020 was approximately ¥956.12 million, a decrease of 4.80% from ¥1.00 billion in 2019[24]. - The net profit after deducting non-recurring gains and losses was approximately ¥700.28 million, an increase of 2.44% from ¥683.58 million in 2019[24]. - The net cash flow from operating activities for 2020 was approximately ¥1.23 billion, an increase of 26.59% compared to ¥972.09 million in 2019[24]. - The total assets at the end of 2020 were approximately ¥13.70 billion, a decrease of 3.65% from ¥14.21 billion at the end of 2019[24]. - The net assets attributable to shareholders at the end of 2020 were approximately ¥8.62 billion, an increase of 3.23% from ¥8.35 billion at the end of 2019[24]. - The basic earnings per share for 2020 were ¥0.69, a decrease of 4.17% from ¥0.72 in 2019[25]. - The weighted average return on equity for 2020 was 11.33%, down from 12.50% in 2019, a decrease of 1.17 percentage points[25]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 3.50 per 10 shares to all shareholders, totaling CNY 291,179,501.13 for the 2019 fiscal year[6]. - For 2020, the company plans to distribute a cash dividend of 3.5 RMB per 10 shares, expected to total approximately 485.30 million RMB, which will account for 50.76% of the net profit attributable to shareholders[126]. - The cash dividend for 2020 is significantly higher than the previous year, reflecting an increase in the payout ratio from 30.70% in 2019 to 50.76% in 2020[126]. - The company has projected ordinary share dividend distribution plans for the past three years, indicating a consistent approach to returning profits to shareholders[127]. - The company has not proposed any cash profit distribution plan for the current reporting period despite having positive distributable profits[128]. Operational Efficiency - The company has established a robust information management system to enhance operational efficiency and competitiveness through digitalization and automation[52]. - The company’s digital factory project has been completed, enhancing efficiency and quality in smart meter production[66]. - The net cash flow from operating activities increased by 26.59% to approximately ¥1.23 billion, attributed to improved management of receivables and payables[87]. Market Expansion and Strategy - The company is actively expanding its market presence both domestically and internationally through various development models including mergers and acquisitions[38]. - The company is focusing on expanding its overseas market presence, with significant achievements in regions such as Saudi Arabia, Sudan, and Nigeria[53]. - The company is actively pursuing overseas market expansion, particularly in regions like Sweden, Saudi Arabia, and India, while aiming to penetrate the North American market[110]. - The company aims to expand its smart electricity distribution business while maintaining existing channel scales, focusing on non-grid users and new energy clients[111]. Healthcare and Medical Services - The healthcare sector has seen a 9% year-on-year growth in the number of hospitals, reaching a total of 35,000 hospitals in China[41]. - The company aims to establish an integrated service platform for hospitals, focusing on pre-hospital, in-hospital, and post-hospital services, while also expanding its internet medical services[38]. - The rehabilitation medical market in China is expected to grow significantly, with an estimated market size of 103.2 billion RMB by 2021[42]. - The company has established strategic partnerships with renowned medical institutions and universities to enhance its healthcare services[38]. - The company is committed to building a complete industry chain from pre-hospital (health check) to in-hospital (general hospital) and post-hospital (rehabilitation, nursing) services[110]. Research and Development - Research and development expenses totaled approximately ¥312.78 million, constituting 4.41% of total revenue[85]. - The company had 736 R&D personnel, making up 12.60% of the total workforce[86]. - The company has developed multiple core technologies in smart power distribution and is a leading provider of overall solutions in this field, focusing on smart metering and energy-saving products[36]. Social Responsibility and Community Engagement - The company has implemented various public welfare activities, including free medical consultations and support for vulnerable groups during traditional festivals[159]. - The company has helped 175 registered poor households achieve employment through vocational training programs[154]. - The company actively promotes energy conservation and environmental protection, continuously improving production processes to reduce energy consumption[156]. - During the pandemic, the company dispatched 19 medical staff to support Wuhan and provided free health check-ups worth 500,000 yuan to frontline workers[160]. Corporate Governance - The board of directors confirmed that all members attended the board meeting, ensuring accountability for the report's accuracy[4]. - The company’s supervisory board effectively monitors the legality and compliance of the board's decisions and management actions[197]. - The company held one shareholders' meeting during the reporting period, ensuring compliance with legal and procedural requirements[194]. - The company has not reported any major environmental accidents during the reporting period, and all emissions were within regulatory standards[161].
三星医疗(601567) - 2020 Q2 - 季度财报
2020-08-24 16:00
Financial Performance - The company reported no profit distribution during the reporting period[4] - The company's operating revenue for the first half of 2020 was CNY 3,489,403,140.54, representing a 12.27% increase compared to the same period last year[15] - The net profit attributable to shareholders decreased by 8.83% to CNY 497,832,519.31 from CNY 546,071,308.94 in the previous year[15] - The net cash flow from operating activities surged by 482.42% to CNY 115,202,933.77, compared to CNY 19,779,983.82 in the same period last year[15] - The basic earnings per share decreased by 7.69% to CNY 0.36, down from CNY 0.39 in the previous year[16] - The company reported non-recurring gains of CNY 151,872,124.88, primarily from government subsidies and other non-operating income[17] - The net profit attributable to shareholders decreased by 8.83% to 49,783.25 million yuan, while the net profit excluding non-recurring gains and losses increased by 20.44% to 34,596.04 million yuan[36] - The company reported a total of CNY 725.23 million in financial assets at fair value, with a change of CNY 240.08 million impacting current profits[48] - The company reported a total loss of 415,970,715.90 CNY in profit distribution[111] - The total comprehensive income for the first half of 2020 was ¥510,670,733.59, down from ¥548,162,499.42 in the previous year, reflecting a decrease of approximately 6.8%[95] Corporate Governance - The board of directors confirmed the accuracy and completeness of the financial report[3] - There were no significant risks or violations of decision-making procedures reported[4] - The company is committed to ensuring the authenticity of the financial report[3] - The board meeting was attended by all directors, ensuring collective oversight[3] - The company appointed Lixin Certified Public Accountants as the auditing firm for the fiscal year 2020, approved at the 2019 annual shareholders' meeting[63] - There were no significant lawsuits or arbitration matters during the reporting period[64] - The company has not distributed profits or increased capital reserves during the reporting period[60] - The company has undergone changes in its board of directors and senior management, with several new appointments[85] Market and Business Development - The company is actively developing smart power distribution products and has mastered several core technologies in metering, communication, and energy saving[20] - The medical services segment focuses on hospital construction, operation, investment mergers, and financing leasing, aiming to create an integrated service platform[21] - The company is expanding its medical services in key regions such as the Yangtze River Delta and the Pearl River Delta, while also looking towards international markets[21] - The company has established a comprehensive product line covering the entire smart power distribution industry chain, positioning itself as a leading provider of smart power solutions[27] - The company has developed a robust international marketing network, with partnerships in over 50 countries, enhancing its global presence[32] - The company has actively expanded its overseas market presence, securing contracts in countries such as Saudi Arabia, Sweden, Indonesia, Brazil, and Colombia, leveraging the "Belt and Road" initiative[38] - The company is focusing on a national chain of rehabilitation services, leveraging advanced rehabilitation concepts and collaborating with renowned medical experts[35] Financial Position - The company's total assets increased by 3.56% to CNY 14,720,376,236.50 from CNY 14,214,526,339.34 at the end of the previous year[16] - The net assets attributable to shareholders decreased by 3.59% to CNY 8,051,142,808.34 from CNY 8,350,885,042.81 at the end of the previous year[15] - The company's total liabilities increased to approximately ¥6.63 billion from ¥5.82 billion, representing a rise of about 13.9%[89] - The equity attributable to shareholders decreased to approximately ¥8.05 billion from ¥8.35 billion, a decline of about 3.5%[89] - The company's total assets as of June 30, 2020, amounted to ¥9,273,258,297.43, compared to ¥8,206,072,410.34 at the end of 2019, indicating a growth of 13%[92] - The company's total liabilities decreased from CNY 2,699,704,373.67 to CNY 2,456,010,769.93, indicating a reduction of approximately 9.0%[103] Risks and Challenges - The company faces management risks due to rapid expansion and entry into the healthcare industry, which may lead to significant changes in net profit compared to the previous year[52] - The company is exposed to intense market competition in the electric meter and 10kV transformer sectors, which could adversely affect profitability[53] - The company’s financing leasing business is expanding, posing risks related to lessees' ability to pay rent on time[58] - The company’s overseas acquisitions and partnerships may encounter operational risks due to differing legal and commercial environments[56] Social Responsibility - The company has invested RMB 100,000 annually from 2018 to 2020 to support the economic development of Badazhen Village in Guizhou Province, focusing on farmer training and employment[74] - A total of 170 registered impoverished individuals were helped to escape poverty during the reporting period[75] - The company provided vocational skills training to 173 individuals, resulting in 173 registered impoverished households achieving employment[75] - The total amount of contracts signed for poverty alleviation projects reached RMB 300,000, with RMB 200,000 already disbursed[76] - The company complies with national environmental protection laws and regulations, with all monitored emissions meeting standards during the reporting period[76] Shareholder Information - The company’s total number of ordinary shareholders reached 36,981 by the end of the reporting period[80] - The top shareholder, Aux Group Co., Ltd., holds 457,719,653 shares, representing 33.01% of the total shares[81] - Zheng Jianjiang, the actual controller, holds 235,036,730 shares, accounting for 16.95%[81] - The total number of shares held by the top ten shareholders amounts to 835,000,000 shares, which is approximately 60.09% of the total shares[81] - The company maintains a stable shareholding structure with no significant fluctuations in shareholding among major shareholders[81] Accounting and Financial Reporting - The financial statements are prepared based on the assumption of going concern, confirming the company's ability to continue operations for at least 12 months from the reporting date[123] - The company adheres to accounting standards, ensuring that financial reports accurately reflect its financial position and operating results[125] - The company recognizes revenue and expenses from newly acquired subsidiaries from the acquisition date to the reporting date, ensuring comprehensive financial reporting[132] - The company has established specific accounting policies and estimates tailored to its operational characteristics, enhancing the accuracy of financial reporting[124] - The company recognizes interest income on held-to-maturity investments using the effective interest method, with gains or losses recognized upon disposal[141]
三星医疗(601567) - 2019 Q4 - 年度财报
2020-04-29 16:00
Financial Performance - The net profit for 2019 was CNY 236,496,718.53, with a statutory reserve of 10% amounting to CNY 23,649,671.85[6] - The total distributable profit at the end of the year was CNY 481,148,349.21 after accounting for dividends paid of CNY 415,970,715.90 for 2018[6] - The company plans to distribute a cash dividend of CNY 2.1 per 10 shares to all shareholders, with the remaining profit carried forward to the next year[6] - The company repurchased shares for a total amount of CNY 26,889,617.28 during the reporting period, which is treated as a cash dividend under regulations[6] - The company's operating revenue for 2019 was CNY 6,739,129,855.23, representing a 14.80% increase compared to CNY 5,870,471,517.37 in 2018[24] - The net profit attributable to shareholders for 2019 was CNY 1,036,046,778.37, a significant increase of 103.91% from CNY 508,079,684.01 in 2018[24] - The net cash flow from operating activities reached CNY 924,598,119.17, up 107.79% from CNY 444,964,503.84 in the previous year[24] - Basic earnings per share for 2019 were CNY 0.75, an increase of 108.33% compared to CNY 0.36 in 2018[25] - The weighted average return on equity rose to 13.40%, an increase of 6.67 percentage points from 6.73% in 2018[25] - The total assets at the end of 2019 were CNY 13,611,133,083.27, a decrease of 4.94% from CNY 14,318,445,773.79 at the end of 2018[24] - The net assets attributable to shareholders increased to CNY 8,041,156,022.25, reflecting a growth of 7.83% from CNY 7,456,957,237.35 in 2018[24] Market and Business Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[1] - The smart power distribution and medical services sectors are the main business areas, with a focus on smart grid and medical service platform development[33] - In the smart power distribution sector, the company has developed core technologies in metering, communication, and energy saving, enhancing its competitive edge[34] - The company has established a comprehensive service platform for hospitals, focusing on construction, operation, investment, and financing leasing[35] - The demand for smart meters is expected to exceed RMB 20 billion annually in the next three years, driven by the replacement of old meters and the introduction of new generation smart meters[37] - The medical services market in China is projected to reach nearly RMB 4 trillion, with a compound annual growth rate exceeding 20%[39] - The company is actively expanding its market presence both domestically and internationally, leveraging strategic partnerships and acquisitions[35] - The government is promoting the development of social medical services, which is expected to create new opportunities for the company in the healthcare sector[40] - The company aims to strengthen its core business in smart power distribution while actively pursuing investments and acquisitions in the healthcare sector[94] - The company plans to expand its medical services by establishing a comprehensive medical system that integrates pre-hospital, in-hospital, and post-hospital care[94] Risks and Challenges - The report includes a detailed risk analysis regarding future developments and potential challenges[9] - The company has faced management risks due to rapid expansion and entry into the healthcare industry, necessitating the recruitment and retention of management and technical talent[99] - The company is exposed to market competition risks in the electric meter and 10kV distribution transformer sectors, which could adversely affect profitability if competitors increase production scale and reduce costs[100] - The company relies heavily on domestic power system users for its smart distribution equipment, making it vulnerable to changes in national policies and investment scales[101] - The company has undertaken overseas mergers and acquisitions, which carry investment and operational risks due to differing legal and commercial environments[102] - The company has experienced risks related to hospital investments, including long payback periods and integration challenges post-acquisition[104] - The company has expanded its financing leasing operations, which introduces risks related to tenant defaults and asset misappropriation[105] Shareholder and Governance - The company has a governance structure that ensures equal rights for all shareholders, particularly minority shareholders, and has held one shareholders' meeting during the reporting period[184] - The company has established a board of directors with 3 independent directors, ensuring compliance with legal and regulatory requirements[186] - The supervisory board effectively oversees the company's operational decisions, financial status, and compliance, safeguarding shareholder interests[187] - The company has appointed independent directors and established a remuneration decision-making process based on performance management systems[176] - The company has disclosed an internal control self-evaluation report, confirming no significant deficiencies in internal controls during the reporting period[196] - The company strictly adhered to information disclosure regulations, completing 45 interim announcements and various periodic reports in a timely manner[190] Social Responsibility and Employee Management - The company actively engaged in social responsibility initiatives, investing 100,000 RMB annually from 2018 to 2020 to support poverty alleviation efforts in Baida Village, Guizhou Province[142] - The company reported helping 15 registered impoverished individuals achieve employment through vocational training programs[143] - The company has maintained a focus on employee rights, providing various levels of training to enhance employee skills and job adaptability[146] - The company has organized various training programs for different levels of employees, including executive training, middle management training, and sales technical service training[181] Financial Adjustments and Reporting - The company implemented changes in accounting policies due to new financial reporting standards, affecting the classification of receivables and payables[123] - The adjustments in financial reporting included a reduction of 87,850 RMB in financial assets measured at fair value and an increase of 445.69 million RMB in trading financial assets[124] - The company reclassified certain investments, resulting in a decrease of 834.81 million RMB in available-for-sale financial assets[125] - The financial report adjustments did not impact the overall financial position but required reclassification of various asset categories[124] - The company is committed to adhering to the revised accounting standards and has made necessary adjustments to retained earnings and other comprehensive income[124] Audit and Compliance - The audit report issued by Lixin Certified Public Accountants was a standard unqualified opinion[5] - The board of directors and senior management confirmed the accuracy and completeness of the financial report[4] - The company has no significant litigation or arbitration matters during the reporting period[128] - An internal control audit report was issued by a certified accounting firm, affirming the company's compliance with accounting standards[200]
三星医疗(601567) - 2018 Q4 - 年度财报
2019-04-22 16:00
Financial Performance - The net profit for 2018 was CNY 111,675,616.69, with a statutory reserve of 10% amounting to CNY 11,167,561.67[5] - The total distributable profit at the end of the year was CNY 684,272,018.43 after accounting for dividends paid of CNY 428,050,354.20 for the previous year[5] - The company plans to distribute a cash dividend of CNY 3 per 10 shares to all shareholders, with the remaining profit carried forward to the next year[5] - The company's operating revenue for 2018 was CNY 5,870,471,517.37, representing a 9.35% increase compared to CNY 5,368,397,769.60 in 2017[21] - The net profit attributable to shareholders for 2018 decreased by 42.95% to CNY 508,079,684.01 from CNY 890,589,037.28 in 2017[21] - The cash flow from operating activities for 2018 was CNY 444,964,503.84, down 52.33% from CNY 933,506,116.98 in 2017[21] - The basic earnings per share for 2018 was CNY 0.36, a decrease of 42.86% compared to CNY 0.63 in 2017[22] - The total assets at the end of 2018 were CNY 14,318,445,773.79, an increase of 12.66% from CNY 12,709,803,764.76 at the end of 2017[21] - The weighted average return on equity for 2018 was 6.73%, down 5.62 percentage points from 12.35% in 2017[22] - The company reported a total of CNY 80,476,133.6 in non-recurring gains and losses for 2018[25] Share Buyback and Dividends - During the buyback period from September 13, 2018, to February 1, 2019, the company repurchased shares for a total of CNY 201,006,095.77, with CNY 174,109,212.82 considered as cash dividends[5] - In 2018, the company distributed cash dividends of 3 RMB per 10 shares, totaling approximately 425.64 million RMB, which accounted for 53.59% of the net profit attributable to shareholders[115] - The company plans to distribute a cash dividend of 3 RMB per 10 shares, totaling approximately 415.97 million RMB, which accounts for 81.87% of the net profit attributable to shareholders for the year 2018[116] - In 2018, the company repurchased shares for a total of 201 million RMB, with 174.11 million RMB considered as cash dividends, representing 34.26% of the net profit attributable to shareholders[119] Operational Risks and Future Outlook - The company has detailed risks associated with its future development in the report, particularly in the section discussing operational conditions[7] - The company emphasizes the importance of investment risk awareness in its forward-looking statements[6] - The company plans to continue focusing on market expansion and new product development in the upcoming fiscal year[25] - The company is focusing on expanding its medical service platform, integrating general and specialized medical services through new constructions, investments, and acquisitions[104] - The company is facing risks related to management due to rapid expansion and entry into the healthcare sector, which requires effective adaptation of its management systems[106] Medical Services and Expansion - The company plans to expand its medical services through hospital construction, operation, and mergers, aiming to create an integrated service platform[31] - The company is focusing on the rehabilitation medical sector, accelerating nationwide expansion, and enhancing its management capabilities through standardized operations[60] - The company has a clear medical development strategy that integrates physical hospitals, online hospitals, and medical insurance, aiming to enhance clinical business capabilities[50] - Mingzhou Hospital achieved revenue of 1.047 billion RMB in 2018, representing a year-on-year growth of 33.78%[61] - The medical services sector reported revenue of 1.296 billion RMB, with a gross margin of 22.92%, which decreased by 5.81 percentage points year-on-year[69] Investments and Acquisitions - The company acquired 46.98 million shares of Tongshang Bank from its controlling shareholder for a total price of 830 million yuan, representing 9% of the bank's total equity[40] - The company invested CNY 1 billion in establishing the Ningbo Meishan Free Trade Port Area Dongzheng Xia De Investment Partnership, focusing on Pre-IPO enterprises[86] - The company acquired a 9% stake in Tongshang Bank for CNY 830 million, with the transaction approved by regulatory authorities during the reporting period[86] - The company also acquired 100% equity of Wenzhou Deep Blue Hospital, with a commitment of a net profit of no less than 8.05 million yuan, achieving an actual net profit of 8.0811 million yuan in 2018[133] Corporate Governance and Compliance - The report includes a standard unqualified audit opinion from Lixin Certified Public Accountants[4] - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[7] - There are no violations of decision-making procedures regarding external guarantees[7] - The company has no major litigation or arbitration matters in the reporting year[127] - The company maintains a good integrity status, with no significant debts overdue or unfulfilled court judgments[127] - The company has a governance structure that ensures equal rights for all shareholders, particularly minority shareholders[188] Market Trends and Industry Insights - The domestic electricity consumption is projected to reach 8 to 8.81 trillion kWh by 2020, with an annual growth rate of 4.6% to 6.6% during the 13th Five-Year Plan[33] - The global smart grid investment is expected to grow from $20.83 billion in 2017 to $50.65 billion by 2022, with a CAGR of 19.40%[36] - The company anticipates that the demand for smart meters will increase significantly, with an expected tender volume exceeding 60 million units in 2019[35] - The number of private hospitals in China reached approximately 20,000 by September 2018, 1.65 times that of public hospitals, reflecting a growing trend in private healthcare[38] - The rehabilitation medical industry in China is projected to grow to 102.3 billion yuan by 2023, with a compound annual growth rate (CAGR) of no less than 18%[39] Employee and Management Structure - The total number of employees in the parent company is 1,511, while the total number of employees in major subsidiaries is 4,311, resulting in a combined total of 5,822 employees[182] - The total pre-tax remuneration for all directors and senior management during the reporting period amounts to 3,473,700 yuan[170] - The company has implemented a salary policy for senior management that includes a basic annual salary and performance-based compensation, with the basic salary determined by factors such as company scale and market wage levels[183] - The company has a training program for various levels of employees, including executives, middle management, and sales personnel, aimed at enhancing their skills and capabilities[184] Shareholder Information - The total number of shareholders at the end of the reporting period was 26,480, down from 29,344 at the end of the previous month[159] - The largest shareholder, Aux Group Co., Ltd., held 457,719,653 shares, accounting for 32.28% of the total shares[161] - The second-largest shareholder, Zheng Jianjiang, held 235,036,730 shares, representing 16.58% of the total shares[161] - The company does not have any strategic investors or significant shareholders holding more than 10% of shares[167] Internal Controls and Auditing - The internal control self-evaluation report has been disclosed, confirming no significant deficiencies in internal controls during the reporting period[198] - The internal control audit report was issued by Lixin Accounting Firm, confirming the company's internal control status[198] - The company has established a comprehensive evaluation mechanism for senior management, focusing on economic efficiency and the achievement of operational goals[197]